Kambugu A - Search Results

1

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.

Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Hakim JG, et al. Among authors: kambugu a. Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3. Lancet Infect Dis. 2018. PMID: 29108797 Free PMC article. Clinical Trial.

2

Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).

Songa PM, Castelnuovo B, Mugasha EB, Ocama P, Kambugu A. Songa PM, et al. Among authors: kambugu a. Clin Infect Dis. 2007 Aug 15;45(4):514-7. doi: 10.1086/520023. Epub 2007 Jul 5. Clin Infect Dis. 2007. PMID: 17638205

3

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P, Kambugu A, Gilks CF, Mugyenyi P, Munderi P, Hakim J, Gibb DM; Development of Antiretroviral Therapy Trial. Reid A, et al. Among authors: kambugu a. Clin Infect Dis. 2008 Apr 15;46(8):1271-81. doi: 10.1086/533468. Clin Infect Dis. 2008. PMID: 18444867

4

Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort.

Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Castelnuovo B, et al. Among authors: kambugu a. Clin Infect Dis. 2009 Sep 15;49(6):965-72. doi: 10.1086/605500. Clin Infect Dis. 2009. PMID: 19673615

5

Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?

Shihab HM, Lutwama F, Piloya T, Castelnuovo B, Kambugu AD, Colebunders R. Shihab HM, et al. J Infect Dev Ctries. 2009 Jun 1;3(5):405-7. doi: 10.3855/jidc.251. J Infect Dev Ctries. 2009. PMID: 19759513 Free article.

6

Sexual behaviors over a 3-year period among individuals with advanced HIV/AIDS receiving antiretroviral therapy in an urban HIV clinic in Kampala, Uganda.

Wandera B, Kamya MR, Castelnuovo B, Kiragga A, Kambugu A, Wanyama JN, Easterbrook P, Sethi AK. Wandera B, et al. Among authors: kambugu a. J Acquir Immune Defic Syndr. 2011 May 1;57(1):62-8. doi: 10.1097/QAI.0b013e318211b3f2. J Acquir Immune Defic Syndr. 2011. PMID: 21297481 Free PMC article.

7

Pre-ART HIV resistance testing in Africa: are we there yet?

Kambugu A. Kambugu A. Lancet Infect Dis. 2012 Apr;12(4):261. doi: 10.1016/S1473-3099(11)70280-8. Epub 2011 Oct 27. Lancet Infect Dis. 2012. PMID: 22036232 No abstract available.

8

Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda.

Reynolds SJ, Sendagire H, Newell K, Castelnuovo B, Nankya I, Kamya M, Quinn TC, Manabe YC, Kambugu A. Reynolds SJ, et al. Among authors: kambugu a. BMC Infect Dis. 2012 Dec 27;12:381. doi: 10.1186/1471-2334-12-381. BMC Infect Dis. 2012. PMID: 23270482 Free PMC article.

9

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. Among authors: kambugu a. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.

10

Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.

Katusiime C, Ocama P, Kambugu A. Katusiime C, et al. Among authors: kambugu a. Afr Health Sci. 2014 Sep;14(3):679-81. doi: 10.4314/ahs.v14i3.25. Afr Health Sci. 2014. PMID: 25352888 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters